menu

Unveiling AOSD: Connecting the Dots in the Spectrum of Still's Disease

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
x
Hello, there.

Disclosures

This presentation is sponsored by Novartis Medical Affairs, and the speakers have been compensated for their time.

Christopher T. Ritchlin, MD, MPH

  • Research: UCB, AbbVie, Amgen
  • Consultant: UCB, AbbVie, Amgen, Janssen, Novartis, Pfizer, Lilly

Petros Efthimiou, MD, FACR

  • Consultant and advisory board: Novartis

Olga Petryna, MD, FACR

  • Consultant: Novartis, Amgen, Pfizer, Mallinckrodt Pharmaceuticals, Horizon, Lilly
Read Full Program Description
CONTINUE TO PROGRAM

Unveiling AOSD: Connecting the Dots in the Spectrum of Still's Disease

6 chapters
Play All
Program Information
Chapters
Recommended

Program Information

Chapter 1
Unveiling AOSD: Connecting the Dots in the Spectrum of Still's Disease
RestartResume

Listen in as medical experts have a conversation on the concept of the continuum of Still’s disease, its burden, and the patient journey.

Chapter 2
video Clinical Features of SJIA and AOSD for Segment 12214
Clinical Features of SJIA and AOSD
Chapter 3
video Case Reviews – Features and Diagnosis of AOSD for Segment 12214
Case Reviews – Features and Diagnosis of AOSD
Chapter 4
video What Are the Criteria to Diagnose AOSD? for Segment 12214
What Are the Criteria to Diagnose AOSD?
Chapter 5
video Why Is Delayed Diagnosis an Ongoing Concern in AOSD? for Segment 12214
Why Is Delayed Diagnosis an Ongoing Concern in AOSD?
Chapter 6
video Case Discussion – Consequences of Delayed Diagnosis in AOSD for Segment 12214
Case Discussion – Consequences of Delayed Diagnosis in AOSD
  • Sponsored by

  • Overview

    Is it time to connect the dots between systemic juvenile idiopathic arthritis (SJIA) and adult-onset Still’s disease (AOSD)? There is a growing recognition that SJIA and AOSD represent the same disease continuum with different ages of onset.1 Both conditions are rare autoinflammatory disorders of unknown etiology.1 In addition to Still’s disease rarity, patients present with varying symptoms and are diagnosed by exclusion of other diseases, which may result in a long time to proper care.2,3 A delay in diagnosis and failure to control disease activity can lead to severe and life-threatening complications.A multidisciplinary team effort and greater disease awareness are necessary to help expedite the therapeutic journey of patients with Still’s disease.5

    Listen in to a discussion panel moderated by Christopher T. Ritchlin, MD with Petros Efthimiou, MD and Olga Petryna, MD as they have a conversation on the concept of the continuum of Still’s disease, its burden, and the patient journey.

    This presentation is sponsored by Novartis Medical Affairs and all speakers have been compensated for their time.

    References

    1. Vastert SJ, Jamilloux Y, Quartier P, et al. Anakinra in children and adults with Still’s disease. Rheumatology. 2019;58(suppl 6):vi9-vi22. doi:10.1093/rheumatology/kez350
    2. Efthimiou P. Diagnosis and management of adult onset Still’s disease. Ann Rheum Dis. 2006;65(5):564-572. doi:10.1136/ard.2005.042143
    3. Pay S, Türkçapar N, Kalyoncu M, et al. A multicenter study of patients with adult-onset Still’s disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol. 2006;25(5):639-644. doi:10.1007/s10067-005-0138-5
    4. Lenert A, Oh Gy, Ombrello MJ, Kim S. Clinical characteristics and comorbidities in adult-onset Still’s disease using a large US administrative claims database. Rheumatol (United Kingdom). 2020;59(7):1725-1733. doi:10.1093/rheumatology/kez622
    5. Pak S, Pham C. Delay in the diagnosis of adult-onset Still’s disease. Cureus. 2017;9(6). doi:10.7759/cureus.1321

    3/21     M-XAT-1399851​

Programs 5/14/21